@BioMarinMedical

Transforming Lives Through Genetic Discovery

This account is intended for HCPs for scientific purposes only. Community guidelines:

[@BioMarinMedical @BioMarinMedical]

Follow us to learn more about the latest scientific information from BioMarin!

Healthcare professionals can request information about BioMarin’s products and clinical trials via the contact details here: https://t.co/xg0ecoW6Xb

If you are a patient looking for information, please speak to your Healthcare Provider.

[@BioMarinMedical @BioMarinMedical]

Just wrapped up a great #ESPE2024! Here are some of the posters and presentations you might have missed: https://t.co/VNYqo3WOd8

[@BioMarinMedical @BioMarinMedical]

Learn more about the #CrescNetRegistry at #ESPE2024. This post is intended for US HCPs only.

[@BioMarinMedical @BioMarinMedical]

We look forward to attending the 62nd Annual #ESPE Meeting next week to collaborate with fellow researchers, clinicians, and healthcare providers who are innovating in the #paediatric #endocrinology space. #ESPE2024

[@BioMarinMedical @BioMarinMedical]

BioMarin is committed to advancing research in growth-related conditions. We're proud to have shared 4 BioMarin-sponsored presentations on our latest advancements at #JSPE2024. Learn more about ongoing research: https://t.co/5gVSXyCaJa.

[@BioMarinMedical @BioMarinMedical]

Our team is looking forward to attending #JSPE2024 later this week to share updates from our research on skeletal conditions like #achondroplasia.

[@BioMarinMedical @BioMarinMedical]

Although #ISDS2024 has come to an end, our commitment to growth-related conditions such as #achondroplasia has never been stronger. We enjoyed interacting with #clinicians, #researchers, and the #SkeletalDysplasia​ community over the last several days. This post is intended for healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

Understand the road map of #achondroplasia at #ISDS2024. Read more: https://t.co/RcEDgjxhlm. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

Preliminary data from a #phase2 trial will be shared at #ISDS2024—learn about the impact of treatment on growth in #RASopathies and ACAN and NPR2 deficiency. Learn more: https://t.co/zHchXN9ugx. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

See results from a study presented at #ISDS2024 to understand the design and objectives of our ACORN study evaluating long-term safety in treated children with #achondroplasia. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

Learn about #phase2 trial results and the impact treatment has on growth for children with #hypochondroplasia at #ISDS2024. Read more: https://t.co/DPoYfIs4Cn. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

See data from the multicenter CLARITY study of patients with #achondroplasia presented at #ISDS2024. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

Data examining the effect of treatment on #BoneStrength in children with #achondroplasia will be presented at #ISDS2024. Learn more: https://t.co/60QnQ6JSTr. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

Join us at #ISDS2024 to hear how a novel CNP analog adjuvant therapy can impact #BoneGrowth and quality in growing mice with moderate-to-severe #OsteogenesisImperfecta. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

Discover the #caregiver perspective on treating children with #achondroplasia at #ISDS2024. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

We look forward to attending #ISDS2024 and engaging with the #SkeletalDysplasia community. Learn more about BioMarin’s commitment to growth-related conditions: https://t.co/QsPJZgh5No. This post is intended for healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

See results from a study evaluating patients with severe #hemophiliaA, recently published in @haemophilia_jnl. This post is intended for US healthcare professionals only. https://t.co/3ViOqMFeDQ

[@BioMarinMedical @BioMarinMedical]

Earlier today, we shared a series of case studies highlighting lessons learned from 5 years of experience in US clinics​ with a treatment for #phenylketonuria. This post is intended for US
healthcare professionals only. #NPKUA2024

[@BioMarinMedical @BioMarinMedical]

Join us at #NPKUA2024 where we are presenting data about the role of comprehensive #phenylketonuria education in #genetics trainees. Learn more about the study: https://t.co/SldTEfTlk8. This post is intended for US healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

We look forward to presenting data at the #NPKUA2024 conference and highlighting our commitment to patients managing #metabolic conditions such as #phenylketonuria. This post is intended for healthcare professionals only.

[@BioMarinMedical @BioMarinMedical]

A heartfelt thank you to all who joined us at #ISTH2024 over the last few days. We enjoyed learning more about advancements in #ClinicalResearch for people with severe #haemophilia and engaging with the medical and scientific community. See you next year! This post is intended for healthcare professionals only.